Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
1:500-1:3000 |
Assay dependent |
Not tested in other applications.
Calculated MW
Positive Control
WSN virus infected DF-1 cells , influenza A virus H1N1-infected H1299
Form
Liquid
Buffer
PBS, 1% BSA, 20% Glycerol
Preservative
0.025% ProClin 300
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
0.11 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Influenza A virus
Immunogen
Recombinant protein encompassing a sequence within the N-terminus region of Influenza A virus H1N1 NA (Neuraminidase) (A/WSN/1933(H1N1). The exact sequence is proprietary.
Purification
Purified by antigen-affinity chromatography.
Conjugation
Unconjugated
RRID
AB_2885621
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
Influenza A Virus Neuraminidase , Influenza A Virus NA
Background
Influenza A subtypes are classified based on the combination of the virus coat glycoproteins hemagglutinin (HA) and neuraminidase (NA) subtypes. There are 16 different HA antigens (H1-H16) and nine different NA antigens (N1-N9) for Influenza A. The extent of infection into host organisms is determined by HA, which interacts with cell surface proteins containing oligosaccharides with terminal sialyl residues.
Research Area